The colposcopy fails to reveal any lesions.
What do the ASCCP guidelines say to do?
ASCCP suggests that women with ASC-US who are hrHPV+ be referred for colposcopy.1
HPV testing to triage ASC-US cytology in women ≥21 years
The ASCCP guidelines support the use of hrHPV DNA testing as an alternative to Pap cytology at 6 and 12 months or immediate colposcopy:
If using Pap cytology only, women with ASC-US cytology on a repeat test are recommended for repeat colposcopy.
Absolute risk of ≥CIN2 according to genotype
The cobas® HPV Test helps you follow the guidelines by providing pooled hrHPV results.
The cobas® HPV Test also provides individual HPV 16 and HPV 18 results to help you identify those women at highest risk who may need more intensive postcolposcopic follow-up
Absolute risk of ≥CIN2 stratified by hrHPV status in the ATHENA ASC-US population2
Her prior Pap was 5 years ago and was reported as negative. Her current pap is also negative, but she tested hrHPV+.
What do the guidelines say?
ACOG, ASCCP, ASCP, and ACS guidelines:
Co-testing in women aged 30-65
The American Cancer Society (ACS), the American Society for Colposcopy and Cervical Pathology (ASCCP), and the American Society for Clinical Pathology (ASCP) jointly issued guidelines for the prevention and early detection of cervical cancer in March 2012. The American Congress of Obstetricians and Gynecologists (ACOG) issued a new practice bulletin on screening for cervical cancer in November 2012. The harmonized ACS, ASCCP, and ASCP guidelines, as well as the ACOG practice bulletin on screening for cervical cancer, state that co-testing using HPV testing in addition to a Pap test every 5 years is preferable to using a Pap test alone every 3 years for women ages 30–65 years.3, 4
Role of genotyping when screening3, 4
ACOG, ASCCP, ASCP, and ASC now recommend that in women 30-65 years of age, individual genotyping for HPV 16 or HPV 16 and 18 be considered when women have a normal cytology (Pap test) result but have positive results on a test for “pooled” high-risk HPV types. As an alternative for managing these patients, the guidelines continue to offer the option of repeating Pap and HPV testing at a one-year interval.
Absolute risk of high-grade cervical disease in women with normal cytology
The cobas® HPV Test helps you adhere to the guidelines by providing pooled hrHPV results and identifying the individual presence of HPV 16 and HPV 18, the highest-risk genotypes.
Absolute risk of ≥CIN2 stratified by hrHPV status in the ATHENA NILM population5